http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Qiuhong Qian (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Qiuhong Qian,Jiaxin Yang,Dongyan Cao,Yan You,Jie Chen,Keng Shen 대한부인종양학회 2014 Journal of Gynecologic Oncology Vol.25 No.4
Objective: To explore appropriate treatment modality of microinvasive cervical cancer (MIC) and to analyze prognosis and risk factors of recurrence. Methods: A cohort of 324 Chinese patients with MIC diagnosed and treated at Peking Union Medical College Hospital was retrospectively reviewed. Demographic features, treatment modalities, pathologic parameters, risk factors of residual disease, survival and risk factors of recurrence were analyzed. Results: Of all patients, 280 cases were staged IA1 and 44 cases staged IA2 MIC. Twenty-five cases (7.7%) were found to have lympho-vascular space involvement (LVSI), but no parametrial involvement or ovarian metastasis was detected. Only one staged IA2 patient with LVSI was found to have lymph node metastasis. 32.4% patients (82/253) had residual diseases after conization. No significant difference of LVSI, lymph node metastasis and residual disease after coniztion was found between stage IA1 and IA2 MIC patients. Multivariate logistic analysis showed positive margin was the only independent risk factor of residual disease after conization (odds ratio [OR], 4.18; p<0.001). Recurrence occurred in five cases, but no mortality was found. Progression-free survival for stage IA1 patients treated by conization or hysterectomy was similar (92.3% and 98.8%, p=0.07). Cox regression analysis revealed LVSI as an independent risk factor for recurrence in stage IA1 patients (OR, 12.14; p=0.01). Conclusion: For stage IA1 patients with negative resection margin and no LVSI, conization can be an ideal treatment modality. For stage IA2 patients, more conservative surgery such as simple hysterectomy may be considered. LVSI is an independent risk factor for recurrence in patients with stage IA1 cervical cancer.
-
Kai Zhang,Qian Sun,Xiaoyu Bai,Peng Liu,Zijian Lyu,Qiuhong Li,Aixiang Li 한국고분자학회 2021 Macromolecular Research Vol.29 No.11
The blending system of chitooligosaccharide (COS) and polyethyleneimine (PEI) was studied as a drug carrier for tumor treatment. Nanoparticles COS/ PEI-PolyI:C-OVA-x (CP-P-O-x) (x=1, 2, 3) were prepared by electrostatic self-assembly of COS and PEI with the immune enhancing drug PolyI:C and the mimic antigen ovalbumin (OVA) using different feeding methods. The results showed that the nanoparticle solution could be stable only when the concentration of the added PEI was above 5.0% w/w. PolyI:C could be coated well and protected from nuclease degradation. The OVA encapsulation efficiency was above 75%. The results of cell viability experiments showed that the blend of COS and PEI had low cytotoxicity. The CP-P-O-1 had a suitable particle size, which was easy to be absorbed and expressed by cells. The results of in vitro immunization showed that due to the addition of PolyI:C, whether OVA was loaded on the inside or on the surface, nanoparticles significantly promoted the secretion of cytokines mouse tumor necrosis factor α (TNF-α) and mouse interferon-γ (IFN-γ). The feeding method mainly had a greater impact on the morphology and size of the nanoparticles, and had little effect on solution stability, OVA encapsulation efficiency, binding ability with PolyI:C, resistance to nuclease degradation and immune performance. CP-P-O-x prepared by the blend system of COS and PEI will be a potential candidate for tumor treatment.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
